Bambusa Therapeutics, Inc.
NASDAQ · BBTXBambusa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing long-acting precision bispecific antibodies for immunology and inflammatory diseases. Its research platform combines established biologic pathways with multi-target antibody engineering and high-concentration subcutaneous formulations designed to support durable treatment and convenient administration. The company’s pipeline includes BBT001, which targets IL-4Rα and IL-31 for atopic dermatitis and other inflammatory skin conditions; BBT002, which targets IL-4Rα and IL-5 for Type 2 inflammatory disorders; and preclinical programs addressing inflammatory bowel disease and autoantibody-driven autoimmune diseases. Bambusa Therapeutics, Inc. operates within the biotechnology and healthcare markets, serving the development needs of patients with chronic immune-mediated conditions and the broader biopharmaceutical ecosystem. Headquartered in Boston, Massachusetts, the company represents a specialized participant in the clinical development of next-generation antibody therapies.
Company profile (no 10-K business section on file)
as of Nov 4, 2026 · today 15.73, 56% of the way from low to high
No dividends on record.
A company that pays none, or whose history has not arrived yet, shows nothing here.
Valuation
Results, trailing twelve months
Balance and cash
Shares and market
Financial statements
Income statement, balance sheet, cash flow, segments
Comps
Valuation, growth and margins against the closest competitors
Filings
Every SEC filing, readable here
Insiders
No sales $58.64M bought · open market, 12 months to Nov 2, 2026
| Insider | Type | Value |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.Nov 2, 2026 | Purchase | $37.36M ↗ |
| RA CAPITAL MANAGEMENT, L.P.Nov 2, 2026 | Purchase | $2.64M ↗ |
| RA CAPITAL MANAGEMENT, L.P.Oct 30, 2026 | Purchase | $3.94M ↗ |
| RA CAPITAL MANAGEMENT, L.P.Oct 30, 2026 | Purchase | $2.70M ↗ |
Funds (13F)
No 13F holdings on record
Congress
No trades disclosed
Short interest
No FINRA short interest on record
In the press
No headlines in the business press in the last 30 days.
Company data reported to the SEC on EDGAR (CIK 2044950).
Member research
Everything on BBTX, in full
Every fiscal year and quarter as filed, the filing reader with highlights and AI summaries, insider and fund activity, congressional trades, short interest history, earnings calls, the full price history and every peer. A 7-day free trial, then a subscription.